Table 3.
Studies of EUS-Guided Chemoablation for PCLs.
| Author, Year | n | Ablative Agents | Type of Cyst | Outcomes | Adverse Events (%) | |
|---|---|---|---|---|---|---|
| Partial Resolution | Complete Resolution | |||||
| Oh 2008 [25] | 14 | Ethanol + Paclitaxel | MCN (2), SCN (3), Others (9) | 14% | 79% | 7% abdominal pain, 7% pancreatitis |
| Oh 2011 [26] | 52 | Ethanol + Paclitaxel | MCN (9), SCN (15), Others (28) | 14% | 67% | 2% abdominal pain, 2% pancreatitis, 2% fever |
| Dewitt 2014 [27] | 22 | Ethanol + Paclitaxel | IPMN (12), MCN (6), SCN (4) | 25% | 50% | 13% abdominal pain, 10% pancreatitis, 3% peritonitis, 3% gastric wall cyst |
| Moyer 2017 [28] | 39 | Paclitaxel/gemcitabine with or without alcohol | IPMN (27), MCN (9), inderterminate (3) | 14% without alcohol, 22% with alcohol | 67% without alcohol, 61 with alcohol | 0% without alcohol vs. 28% with alcohol (22% abdominal pain, 6% pancreatitis) |
| Choi 2017 [29] | 164 | Ethanol + Paclitaxel | IPMN (11), MCN (71), SCN (16), Others (66) | 20% | 72% | 4% pancreatitis, 1% pseudocyst, 1% abscess, 4% other |
| Othman 2022 [78] | 19 | Large surface area microparticle paclitaxel | IPMN (19), MCN (2) | -- | 71% decreased in size (35% had >30% reduction) | 6% abdominal discomfort, 6% edema, 5% fatigue, 5% headaches |
| Krishna 2024 [79] | 6 | Large surface area microparticle paclitaxel | IPMN (6) | 74% mean surface area reduction | 5% pancreatitis | |
IPMN: intraductal papillary mucinous and cystic neoplasms; SCN: serous cystic neoplasm; MCN: mucinous cystic neoplasm.